skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 63,434  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: Database: PubMed Central remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
Material Type:
Article 		Add to My Research

Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

PloS one, 2019-09, Vol.14 (9), p.e0223287-e0223287 [Peer Reviewed Journal]

COPYRIGHT 2019 Public Library of Science ;COPYRIGHT 2019 Public Library of Science ;2019 Mangia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Mangia et al 2019 Mangia et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0223287 ;PMID: 31553772

Full text available

Citations Cited by
2
Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
Material Type:
Article 		Add to My Research

Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice

BMC pulmonary medicine, 2022-03, Vol.22 (1), p.113-113, Article 113 [Peer Reviewed Journal]

COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1471-2466 ;EISSN: 1471-2466 ;DOI: 10.1186/s12890-022-01876-5 ;PMID: 35351085

Full text available

Citations Cited by
3
Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Material Type:
Article 		Add to My Research

Short telomeres are a risk factor for idiopathic pulmonary fibrosis

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (35), p.13051-13056 [Peer Reviewed Journal]

Copyright 2008 The National Academy of Sciences of the United States of America ;Copyright National Academy of Sciences Sep 2, 2008 ;2008 by The National Academy of Sciences of the USA ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.0804280105 ;PMID: 18753630

Full text available

Citations Cited by
4
Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorbeta;1-Driven Lung Fibrosis
Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorbeta;1-Driven Lung Fibrosis
Material Type:
Article 		Add to My Research

Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorbeta;1-Driven Lung Fibrosis

Frontiers in pharmacology, 2020-11 [Peer Reviewed Journal]

COPYRIGHT 2020 Frontiers Research Foundation ;ISSN: 1663-9812 ;EISSN: 1663-9812

Full text available

Citations Cited by
5
Emerging role of HMGB1 in fibrotic diseases
Emerging role of HMGB1 in fibrotic diseases
Material Type:
Article 		Add to My Research

Emerging role of HMGB1 in fibrotic diseases

Journal of cellular and molecular medicine, 2014-12, Vol.18 (12), p.2331-2339 [Peer Reviewed Journal]

2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;Copyright © 2014 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine ;2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. 2014 ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.12419 ;PMID: 25284457

Full text available

Citations Cited by
6
Cystic fibrosis: a clinical view
Cystic fibrosis: a clinical view
Material Type:
Article 		Add to My Research

Cystic fibrosis: a clinical view

Cellular and molecular life sciences : CMLS, 2017-01, Vol.74 (1), p.129-140 [Peer Reviewed Journal]

Springer International Publishing 2016 ;Cellular and Molecular Life Sciences is a copyright of Springer, 2017. ;ISSN: 1420-682X ;EISSN: 1420-9071 ;DOI: 10.1007/s00018-016-2393-9 ;PMID: 27709245

Full text available

Citations Cited by
7
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Material Type:
Article 		Add to My Research

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

American journal of respiratory and critical care medicine, 2013-06, Vol.187 (11), p.1219-1225 [Peer Reviewed Journal]

2014 INIST-CNRS ;Copyright American Thoracic Society Jun 1, 2013 ;Copyright © 2013 by the American Thoracic Society 2013 ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.201301-0153OC ;PMID: 23590265

Full text available

Citations Cited by
8
Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis
Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis
Material Type:
Article 		Add to My Research

Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis

PloS one, 2013-10, Vol.8 (10), p.e76451 [Peer Reviewed Journal]

2013 Vittal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Vittal et al 2013 Vittal et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0076451 ;PMID: 24204629

Full text available

Citations Cited by
9
Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length
Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length
Material Type:
Article 		Add to My Research

Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length

Thorax, 2021-12, Vol.76 (12), p.1242-1245 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2021-217031 ;PMID: 33927016

Full text available

Citations Cited by
10
Pulmonary fibrosis: patterns and perpetrators
Pulmonary fibrosis: patterns and perpetrators
Material Type:
Article 		Add to My Research

Pulmonary fibrosis: patterns and perpetrators

The Journal of clinical investigation, 2012-08, Vol.122 (8), p.2756-2762 [Peer Reviewed Journal]

COPYRIGHT 2012 American Society for Clinical Investigation ;COPYRIGHT 2012 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Aug 2012 ;Copyright © 2012, American Society for Clinical Investigation 2012 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci60323 ;PMID: 22850886

Full text available

Citations Cited by
11
Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
Material Type:
Article 		Add to My Research

Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44

The Journal of experimental medicine, 2011-07, Vol.208 (7), p.1459-1471 [Peer Reviewed Journal]

2011 Li et al. 2011 ;ISSN: 0022-1007 ;EISSN: 1540-9538 ;DOI: 10.1084/jem.20102510 ;PMID: 21708929

Full text available

Citations Cited by
12
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Material Type:
Article 		Add to My Research

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

American journal of respiratory and critical care medicine, 2022-05, Vol.205 (9), p.e18-e47 [Peer Reviewed Journal]

Copyright American Thoracic Society May 1, 2022 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.202202-0399st ;PMID: 35486072

Full text available

Citations Cited by
13
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
Material Type:
Article 		Add to My Research

Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis

PLoS genetics, 2018-11, Vol.14 (11), p.e1007723-e1007723 [Peer Reviewed Journal]

COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Sharma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Sharma et al 2018 Sharma et al ;ISSN: 1553-7404 ;ISSN: 1553-7390 ;EISSN: 1553-7404 ;DOI: 10.1371/journal.pgen.1007723 ;PMID: 30444886

Full text available

Citations Cited by
14
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Material Type:
Article 		Add to My Research

A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis

Scientific reports, 2019-05, Vol.9 (1), p.7234, Article 7234 [Peer Reviewed Journal]

The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-43652-2 ;PMID: 31076617

Full text available

Citations Cited by
15
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis
Material Type:
Article 		Add to My Research

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis

Thorax, 2013-05, Vol.68 (5), p.436-441 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2013 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2012-201786 ;PMID: 23321605 ;CODEN: THORA7

Full text available

Citations Cited by
16
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
Material Type:
Article 		Add to My Research

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

Annals of the rheumatic diseases, 2019-09, Vol.78 (9), p.1260-1268 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2019-215119 ;PMID: 31129606

Full text available

Citations Cited by
17
Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Material Type:
Article 		Add to My Research

Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis

Nature communications, 2020-02, Vol.11 (1), p.1064-14, Article 1064 [Peer Reviewed Journal]

This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-14344-7 ;PMID: 32111836

Full text available

Citations Cited by
18
Regulation of Transforming Growth Factor-β1-driven Lung Fibrosis by Galectin-3
Regulation of Transforming Growth Factor-β1-driven Lung Fibrosis by Galectin-3
Material Type:
Article 		Add to My Research

Regulation of Transforming Growth Factor-β1-driven Lung Fibrosis by Galectin-3

American journal of respiratory and critical care medicine, 2012-03, Vol.185 (5), p.537-546 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright © 2012 by the American Thoracic Society 2012 ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.201106-0965oc ;PMID: 22095546

Full text available

Citations Cited by
19
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
Material Type:
Article 		Add to My Research

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections

American journal of respiratory and critical care medicine, 2017-06, Vol.195 (12), p.1617-1628 [Peer Reviewed Journal]

Copyright American Thoracic Society Jun 15, 2017 ;Copyright © 2017 by the American Thoracic Society 2017 ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.201609-1954OC ;PMID: 28222269

Full text available

Citations Cited by
20
Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR
Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR
Material Type:
Article 		Add to My Research

Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR

Cellular and molecular life sciences : CMLS, 2021-12, Vol.78 (23), p.7813-7829 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 ;2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. ;The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1420-682X ;ISSN: 1420-9071 ;EISSN: 1420-9071 ;DOI: 10.1007/s00018-021-03994-5 ;PMID: 34714360

Full text available

Citations Cited by

Results 1 - 20 of 63,434  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (60,245)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1960  (455)
  2. 1960 To 1975  (742)
  3. 1976 To 1991  (1,693)
  4. 1992 To 2008  (7,158)
  5. After 2008  (53,373)
  6. More options open sub menu

Subject 

  1. Science & Technology  (51,433)
  2. Life Sciences & Biomedicine  (43,573)
  3. Fibrosis  (31,581)
  4. Humans  (27,555)
  5. Animals  (15,733)
  6. Male  (14,778)
  7. Cystic Fibrosis  (12,704)
  8. Female  (11,444)
  9. Inflammation  (10,044)
  10. Proteins  (8,633)
  11. Mice  (8,611)
  12. Science & Technology - Other Topics  (7,884)
  13. Multidisciplinary Sciences  (7,690)
  14. Patients  (7,420)
  15. Pulmonary Fibrosis  (7,068)
  16. Gene Expression  (6,552)
  17. Lung Diseases  (6,392)
  18. Adult  (6,261)
  19. Middle Aged  (6,020)
  20. Biochemistry & Molecular Biology  (5,878)
  21. More options open sub menu

Language 

  1. English  (62,742)
  2. Japanese  (8,067)
  3. Portuguese  (742)
  4. Korean  (459)
  5. Chinese  (85)
  6. Turkish  (69)
  7. French  (52)
  8. Norwegian  (50)
  9. Spanish  (42)
  10. Italian  (27)
  11. Polish  (6)
  12. German  (6)
  13. Croatian  (3)
  14. Welsh  (1)
  15. Russian  (1)
  16. Afrikaans  (1)
  17. Latin  (1)
  18. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait